Back to Search
Start Over
Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma
- Source :
- Headneck. 28(10)
- Publication Year :
- 2006
-
Abstract
- Background. The purpose of this study was to evaluate the efficacy and toxicity of cisplatin plus gemcitabine as induction chemotherapy in advanced nasopharyngeal carci- noma (NPC). Methods. Thirty-seven patients with stage IV(A-B) NPC were treated with 3 cycles of cisplatin plus gemcitabine (cisplatin 80 mg/m 2 on day 1; gemcitabine 1250 mg/m 2 on days 1 and 8) 3-weekly as induction chemotherapy, followed by another 3 cycles of concurrent cisplatin (100 mg/m 2 on day 1) 3-weekly with accelerated radiotherapy (RT) at 70 Gy in 2-Gy fractions, 6 daily fractions per week. Results. The overall response rate to induction chemother- apy was > 90%, and side effects other than uncomplicated he- matologic toxicities were uncommon. All patients completed RT, with 92% receiving � 5 cycles of chemotherapy. At a median fol- low-up of 2.9 years, the 3-year overall survival (OS) and disease- free survival (DFS) rates were 76% and 63%, respectively. Conclusions. Cisplatin plus gemcitabine is a well-tolerated, effective, and convenient induction chemotherapy regimen and warrants further studies to confirm its benefit in advanced NPC. V C 2006 Wiley Periodicals, Inc. Head Neck 28: 880-887, 2006
- Subjects :
- Oncology
Adult
Male
medicine.medical_specialty
medicine.drug_class
medicine.medical_treatment
Antimetabolite
Deoxycytidine
Drug Administration Schedule
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Survival rate
Aged
Neoplasm Staging
Retrospective Studies
Cisplatin
Chemotherapy
business.industry
Remission Induction
Induction chemotherapy
Nasopharyngeal Neoplasms
Radiotherapy Dosage
Middle Aged
medicine.disease
Combined Modality Therapy
Gemcitabine
Surgery
Survival Rate
Regimen
Treatment Outcome
Otorhinolaryngology
Nasopharyngeal carcinoma
Quality of Life
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 10433074
- Volume :
- 28
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Headneck
- Accession number :
- edsair.doi.dedup.....10b3ac32e4fc4fe365b61d94f4d181f7